Tirdzniecība ADMA Biologics, Inc. - ADMA CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.0282 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.024068% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.001846% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 3.0706 |
| Atvērt* | 3.0207 |
| Izmaiņas par 1 gadu* | 97.43% |
| Dienas Diapazons* | 2.9809 - 3.0806 |
| 52 ned Diapazons | 1.43-3.98 |
| Vidējais apjoms (10 dienas) | 3.08M |
| Vidējais apjoms (3 mēneši) | 50.06M |
| Tirgus Kapitalizācija | 670.69M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 217.76M |
| Ieņēmumi | 130.48M |
| EPS | -0.37 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 0.93 |
| Nākamās Peļņas Datums | Mar 23, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Mar 21, 2023 | 3.0706 | 0.0300 | 0.99% | 3.0406 | 3.1703 | 3.0406 |
| Mar 20, 2023 | 3.0507 | -0.0299 | -0.97% | 3.0806 | 3.1005 | 2.9310 |
| Mar 17, 2023 | 3.0606 | -0.0298 | -0.96% | 3.0904 | 3.1204 | 3.0207 |
| Mar 16, 2023 | 3.1105 | 0.0300 | 0.97% | 3.0805 | 3.1703 | 3.0506 |
| Mar 15, 2023 | 3.1105 | 0.0001 | 0.00% | 3.1104 | 3.1902 | 3.0806 |
| Mar 14, 2023 | 3.2002 | -0.0099 | -0.31% | 3.2101 | 3.2600 | 3.1603 |
| Mar 13, 2023 | 3.1803 | 0.1696 | 5.63% | 3.0107 | 3.2201 | 3.0008 |
| Mar 10, 2023 | 3.0806 | -0.1594 | -4.92% | 3.2400 | 3.2600 | 3.0307 |
| Mar 9, 2023 | 3.2600 | -0.1496 | -4.39% | 3.4096 | 3.4395 | 3.2102 |
| Mar 8, 2023 | 3.3896 | 0.0100 | 0.30% | 3.3796 | 3.4495 | 3.3497 |
| Mar 7, 2023 | 3.3797 | 0.0200 | 0.60% | 3.3597 | 3.4495 | 3.2998 |
| Mar 6, 2023 | 3.3398 | -0.0697 | -2.04% | 3.4095 | 3.4295 | 3.2999 |
| Mar 3, 2023 | 3.3996 | -0.0897 | -2.57% | 3.4893 | 3.4893 | 3.3697 |
| Mar 2, 2023 | 3.4395 | -0.0698 | -1.99% | 3.5093 | 3.5392 | 3.4395 |
| Mar 1, 2023 | 3.5292 | -0.0099 | -0.28% | 3.5391 | 3.6489 | 3.5292 |
| Feb 28, 2023 | 3.5392 | 0.0798 | 2.31% | 3.4594 | 3.5890 | 3.4594 |
| Feb 27, 2023 | 3.4694 | 0.0599 | 1.76% | 3.4095 | 3.5192 | 3.3996 |
| Feb 24, 2023 | 3.4096 | 0.0101 | 0.30% | 3.3995 | 3.4694 | 3.3995 |
| Feb 23, 2023 | 3.4893 | -0.0100 | -0.29% | 3.4993 | 3.5192 | 3.4594 |
| Feb 22, 2023 | 3.4893 | -0.0299 | -0.85% | 3.5192 | 3.5591 | 3.4594 |
ADMA Biologics, Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 80.9426 | 42.2198 | 29.3491 | 16.9853 | 22.7606 |
| Ienākumi | 80.9426 | 42.2198 | 29.3491 | 16.9853 | 22.7606 |
| Cost of Revenue, Total | 79.7693 | 61.2914 | 39.5042 | 42.1946 | 29.1643 |
| Bruto Peļņa | 1.17329 | -19.0716 | -10.1552 | -25.2094 | -6.40376 |
| Kopējie Darbības Izdevumi | 139.316 | 106.143 | 80.7359 | 77.2742 | 63.2808 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 55.1856 | 39.2209 | 28.0804 | 30.3085 | 24.5966 |
| Pētniecība un Attīstība | 3.64606 | 5.90701 | 2.34385 | 3.92612 | 6.22959 |
| Neparedzēti Izdevumi (Ienākumi) | 0 | -0.9918 | 9.9625 | 0 | 2.05561 |
| Darbības Izdevumi | -58.3737 | -63.9231 | -51.3868 | -60.2889 | -40.5202 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -13.0223 | -11.6969 | -8.19259 | -5.32738 | -3.22862 |
| Citi, Neto | -0.25158 | -0.12853 | -0.22732 | -0.12712 | -0.01014 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Neto Ienākumi | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Atšķaidītie Neto Ienākumi | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Atšķaidītie Ienākumi par Akcijām | 139.579 | 86.1451 | 54.3481 | 45.1889 | 22.896 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.51331 | -0.87931 | -0.88833 | -1.45486 | -1.9112 |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.51331 | -0.89083 | -0.91713 | -1.45486 | -1.82142 |
| Depreciation / Amortization | 0.71535 | 0.71535 | 0.84494 | 0.84494 | 1.23467 |
| Ārkārtas Posteņi Kopā | 0 | ||||
| Gain (Loss) on Sale of Assets | 0 | 11.5274 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 29.1031 | 26.3829 | 20.6805 | 17.8306 | 16.0486 |
| Ienākumi | 29.1031 | 26.3829 | 20.6805 | 17.8306 | 16.0486 |
| Cost of Revenue, Total | 25.441 | 22.8714 | 20.2952 | 18.8326 | 17.7701 |
| Bruto Peļņa | 3.66204 | 3.51149 | 0.38534 | -1.00203 | -1.7215 |
| Kopējie Darbības Izdevumi | 50.5881 | 39.5741 | 35.1176 | 33.4118 | 31.2129 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 17.6742 | 15.7948 | 13.873 | 13.2415 | 12.2763 |
| Pētniecība un Attīstība | 0.62411 | 0.72899 | 0.77056 | 1.15887 | 0.98765 |
| Depreciation / Amortization | 0.17884 | 0.17884 | 0.17884 | 0.17884 | 0.17884 |
| Darbības Izdevumi | -21.485 | -13.1912 | -14.4371 | -15.5812 | -15.1643 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -3.35597 | -3.31343 | -3.29442 | -3.24075 | -3.17369 |
| Citi, Neto | -0.16688 | -0.1448 | 0.01855 | -0.08332 | -0.042 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -25.0079 | -16.6494 | -17.7129 | -18.9053 | -18.3799 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -25.0079 | -16.6494 | -17.7129 | -18.9053 | -18.3799 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -25.0079 | -16.6494 | -17.7129 | -18.9053 | -18.3799 |
| Neto Ienākumi | -25.0079 | -16.6494 | -17.7129 | -18.9053 | -18.3799 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -25.0079 | -16.6494 | -17.7129 | -18.9053 | -18.3799 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -25.0079 | -16.6494 | -17.7129 | -18.9053 | -18.3799 |
| Atšķaidītie Neto Ienākumi | -25.0079 | -16.6494 | -17.7129 | -18.9053 | -18.3799 |
| Atšķaidītie Ienākumi par Akcijām | 195.872 | 181.267 | 133.77 | 127.416 | 115.662 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.12767 | -0.09185 | -0.13241 | -0.14837 | -0.15891 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.09362 | -0.09185 | -0.13241 | -0.14837 | -0.15891 |
| Neparedzēti Izdevumi (Ienākumi) | 6.66994 | 0 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 208.729 | 153.741 | 85.8204 | 44.5296 | 62.3416 |
| Nauda un Īstermiņa Ieguldījumi | 51.0891 | 55.9212 | 26.7521 | 22.7549 | 43.1076 |
| Nauda un Ekvivalenti | 51.0891 | 55.9212 | 26.7521 | 22.7549 | 43.1076 |
| Īstermiņa Ieguldījumi | |||||
| Debitoru Parādu Kopsumma, Neto | 28.5769 | 13.2373 | 3.46992 | 1.39244 | 3.88015 |
| Accounts Receivable - Trade, Net | 28.5769 | 13.2373 | 3.46992 | 1.39244 | 3.88015 |
| Total Inventory | 124.724 | 81.5356 | 53.0647 | 18.6162 | 12.6282 |
| Prepaid Expenses | 4.33925 | 3.04647 | 2.53359 | 1.76616 | 1.22565 |
| Total Assets | 276.253 | 207.673 | 127.091 | 88.8765 | 108.019 |
| Property/Plant/Equipment, Total - Net | 58.1977 | 45.8523 | 33.1413 | 30.1157 | 30.4669 |
| Property/Plant/Equipment, Total - Gross | 71.4696 | 54.7162 | 38.8663 | 33.5368 | 31.7528 |
| Accumulated Depreciation, Total | -13.2718 | -8.86394 | -5.72496 | -3.42103 | -1.28592 |
| Other Long Term Assets, Total | 4.0674 | 2.10698 | 1.44004 | 6.69725 | 6.83155 |
| Total Current Liabilities | 30.3783 | 19.9474 | 14.0279 | 9.62505 | 9.44018 |
| Accounts Payable | 12.4294 | 11.0737 | 9.17459 | 5.90039 | 5.92087 |
| Accrued Expenses | 16.7941 | 8.73083 | 4.71047 | 3.58182 | 3.37648 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 1.15482 | 0.14283 | 0.14283 | 0.14283 | 0.14283 |
| Total Liabilities | 135.08 | 119.424 | 100.898 | 69.1061 | 67.6861 |
| Total Long Term Debt | 94.8662 | 92.9689 | 83.1992 | 44.075 | 42.9709 |
| Long Term Debt | 94.8662 | 92.9689 | 83.1992 | 44.075 | 42.9709 |
| Other Liabilities, Total | 9.8356 | 6.50774 | 3.67047 | 15.406 | 15.275 |
| Total Equity | 141.173 | 88.2494 | 26.1931 | 19.7704 | 40.3328 |
| Common Stock | 0.01958 | 0.01049 | 0.00593 | 0.00464 | 0.00453 |
| Additional Paid-In Capital | 553.266 | 428.704 | 290.904 | 236.203 | 191.022 |
| Retained Earnings (Accumulated Deficit) | -412.113 | -340.465 | -264.717 | -216.437 | -150.694 |
| Total Liabilities & Shareholders’ Equity | 276.253 | 207.673 | 127.091 | 88.8765 | 108.019 |
| Total Common Shares Outstanding | 195.814 | 104.903 | 59.3184 | 46.3531 | 36.7255 |
| Other Current Assets, Total | 0 | 1.5 | |||
| Goodwill, Net | 3.52951 | 3.52951 | 3.52951 | 3.52951 | 3.52951 |
| Intangibles, Net | 1.72877 | 2.44412 | 3.15947 | 4.00441 | 4.84935 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 239.8 | 208.729 | 174.785 | 171.355 | 177.277 |
| Nauda un Īstermiņa Ieguldījumi | 69.505 | 51.0891 | 34.4106 | 42.409 | 61.9657 |
| Nauda un Ekvivalenti | 69.505 | 51.0891 | 34.4106 | 42.409 | 61.9657 |
| Debitoru Parādu Kopsumma, Neto | 25.6296 | 28.5769 | 20.3926 | 23.5446 | 15.362 |
| Accounts Receivable - Trade, Net | 25.6296 | 28.5769 | 20.3926 | 23.5446 | 15.362 |
| Total Inventory | 139.146 | 124.724 | 114.123 | 99.6997 | 94.1462 |
| Prepaid Expenses | 5.5193 | 4.33925 | 5.85905 | 5.70186 | 5.80261 |
| Total Assets | 308.033 | 276.253 | 238.64 | 232.814 | 235.667 |
| Property/Plant/Equipment, Total - Net | 60.3271 | 58.1977 | 55.0847 | 53.316 | 50.3729 |
| Property/Plant/Equipment, Total - Gross | 75.0076 | 71.4696 | 67.2809 | 64.2715 | 60.2769 |
| Accumulated Depreciation, Total | -14.6804 | -13.2718 | -12.1962 | -10.9555 | -9.90401 |
| Goodwill, Net | 3.52951 | 3.52951 | 3.52951 | 3.52951 | 3.52951 |
| Intangibles, Net | 1.54993 | 1.72877 | 1.90761 | 2.08645 | 2.26528 |
| Other Long Term Assets, Total | 2.82575 | 4.0674 | 3.33351 | 2.52666 | 2.22278 |
| Total Current Liabilities | 31.5665 | 30.3783 | 32.3372 | 18.1864 | 21.2057 |
| Accounts Payable | 14.1151 | 12.4294 | 17.2828 | 6.16747 | 12.1529 |
| Accrued Expenses | 14.2198 | 16.7941 | 13.0301 | 10.7303 | 8.14151 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 3.23159 | 1.15482 | 2.02432 | 1.28866 | 0.91137 |
| Total Liabilities | 181.099 | 135.08 | 135.86 | 121.22 | 123.163 |
| Total Long Term Debt | 138.423 | 94.8662 | 94.363 | 93.877 | 93.4127 |
| Long Term Debt | 138.423 | 94.8662 | 94.363 | 93.877 | 93.4127 |
| Other Liabilities, Total | 11.1099 | 9.8356 | 9.15999 | 9.15685 | 8.54454 |
| Total Equity | 126.933 | 141.173 | 102.78 | 111.594 | 112.504 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.01964 | 0.01958 | 0.01383 | 0.01319 | 0.0123 |
| Additional Paid-In Capital | 564.034 | 553.266 | 498.23 | 489.331 | 471.337 |
| Retained Earnings (Accumulated Deficit) | -437.121 | -412.113 | -395.463 | -377.75 | -358.845 |
| Total Liabilities & Shareholders’ Equity | 308.033 | 276.253 | 238.64 | 232.814 | 235.667 |
| Total Common Shares Outstanding | 196.348 | 195.814 | 138.314 | 131.872 | 123.045 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -71.6476 | -75.7486 | -48.2793 | -65.7434 | -43.759 |
| Nauda no Darbības | -112.369 | -102.003 | -76.1935 | -62.6787 | -37.2718 |
| Nauda no Darbības | 5.4955 | 3.94229 | 3.25815 | 3.4464 | 2.6923 |
| Bezskaidras Naudas Preces | 5.46355 | 3.58462 | 2.33044 | 3.30681 | 4.07714 |
| Samaksātie Procenti Naudā | 11.1595 | 10.2676 | 8.11223 | 4.39997 | 2.29359 |
| Izmaiņas Apgrozāmajā Kapitālā | -51.6804 | -33.7813 | -33.5028 | -3.68844 | -0.28224 |
| Nauda no Ieguldījumu Darbībām | -13.5113 | -12.7247 | -3.81184 | -2.0956 | 15.2139 |
| Kapitālie Izdevumi | -13.5113 | -12.7267 | -3.81184 | -2.0956 | -2.67633 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 0 | 0.002 | 0 | 17.8902 | |
| Nauda no Darbībām ar Finansēšanu | 121.048 | 143.897 | 80.0026 | 42.9216 | 60.7506 |
| Naudas Plūsma Finansēšanas Posteņos | -0.0616 | -0.83 | -10.9395 | 0 | -3.44017 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 121.144 | 131.209 | 48.4721 | 42.9578 | 39.2074 |
| Parādu Izsniegšana (Atkāpšanās), Neto | -0.0343 | 13.5179 | 42.47 | -0.03628 | 24.9834 |
| Neto Izmaiņas Naudā | -4.83203 | 29.169 | -0.00272 | -21.8527 | 38.6927 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -25.0079 | -71.6476 | -54.9982 | -37.2852 | -18.3799 |
| Cash From Operating Activities | -26.0134 | -112.369 | -78.9037 | -65.4914 | -33.2291 |
| Cash From Operating Activities | 1.59022 | 5.4955 | 3.97779 | 2.55562 | 1.22963 |
| Non-Cash Items | 8.86246 | 5.46355 | 3.64236 | 2.50146 | 1.19026 |
| Cash Interest Paid | 2.52599 | 11.1595 | 8.34697 | 5.53428 | 2.75196 |
| Changes in Working Capital | -11.4582 | -51.6804 | -31.5257 | -33.2632 | -17.2691 |
| Cash From Investing Activities | -2.84209 | -13.5113 | -9.8354 | -7.04674 | -2.57116 |
| Capital Expenditures | -2.84209 | -13.5113 | -9.8354 | -7.04674 | -2.57116 |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
| Cash From Financing Activities | 47.2713 | 121.048 | 67.2286 | 59.0259 | 41.8448 |
| Financing Cash Flow Items | -4.46973 | -0.0616 | -0.0616 | -0.05931 | -0.05931 |
| Issuance (Retirement) of Stock, Net | 0 | 121.144 | 67.3157 | 59.1021 | 41.9125 |
| Issuance (Retirement) of Debt, Net | 51.7411 | -0.0343 | -0.02551 | -0.01686 | -0.00836 |
| Net Change in Cash | 18.4158 | -4.83203 | -21.5106 | -13.5122 | 6.04456 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.1941 | 13488055 | 1946140 | 2022-12-31 | LOW |
| Perceptive Advisors LLC | Private Equity | 5.465 | 11900255 | 966868 | 2022-12-31 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.0548 | 11007209 | 1583787 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.9762 | 10835875 | 1545176 | 2022-12-31 | LOW |
| NWQ Investment Management Company, LLC | Investment Advisor/Hedge Fund | 4.8736 | 10612600 | 3727960 | 2021-12-31 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 3.9073 | 8508409 | 2664613 | 2022-12-31 | MED |
| Stonepine Capital Management, LLC | Investment Advisor/Hedge Fund | 3.1871 | 6940000 | 1940000 | 2022-12-31 | MED |
| Magnetar Capital Partners LP | Investment Advisor/Hedge Fund | 2.8414 | 6187316 | 1815908 | 2022-12-31 | HIGH |
| AWM Investment Company, Inc. | Investment Advisor/Hedge Fund | 2.7623 | 6015000 | 1000000 | 2022-12-31 | LOW |
| Millennium Management LLC | Hedge Fund | 2.4324 | 5296781 | 3569778 | 2022-12-31 | HIGH |
| Nuveen Asset Management, LLC | Investment Advisor/Hedge Fund | 1.8845 | 4103514 | -883582 | 2022-12-31 | LOW |
| Velan Capital Investment Management LP | Investment Advisor/Hedge Fund | 1.8369 | 4000000 | -1269155 | 2022-12-31 | MED |
| Invesco Advisers, Inc. | Investment Advisor | 1.7886 | 3894678 | 813693 | 2022-12-31 | LOW |
| Aisling Capital, LLC | Private Equity | 1.6604 | 3615671 | 0 | 2022-04-15 | |
| Nuveen LLC | Pension Fund | 1.5839 | 3448993 | -267644 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5553 | 3386852 | 100723 | 2022-12-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.364 | 2970124 | 1530127 | 2022-12-31 | HIGH |
| Altium Capital Management LP | Investment Advisor/Hedge Fund | 1.318 | 2870000 | -13710 | 2022-12-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 1.2959 | 2821903 | 558990 | 2022-12-31 | MED |
| Caligan Partners, LP | Hedge Fund | 1.2289 | 2676093 | -8217144 | 2022-12-31 | MED |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group500K+
Tirgotāji
92K+
Ikmēneša aktīvie klienti
$53M+
Ikmēneša ieguldījumu apjoms
$30M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
ADMA Biologics, Inc. Company profile
Par ADMA Biologics, Inc.
ADMA Biologics, Inc. ir biofarmācijas uzņēmums. Tas izstrādā, ražo un tirgo specializētus bioloģiskos preparātus uz plazmas bāzes infekcijas slimību ārstēšanai un profilaksei. Uzņēmums nodarbojas ar cilvēka plazmas un no plazmas iegūtu terapeitisko līdzekļu izstrādi un komercializāciju. Uzņēmuma pacientu vidū ir personas ar novājinātu imūnsistēmu, kurām ir imūndeficīta traucējumi un kuras medicīnisku iemeslu dēļ ir imūnsistēmas nomāktas. Uzņēmuma kandidātprodukti ir BIVIGAM, intravenoza imūnglobulīna (IVIG) preparāts, kas paredzēts primārā humānā imūndeficīta (PI) ārstēšanai; ASCENIV, IVIG preparāts, kas paredzēts PI ārstēšanai, un Nabi-HB, kas paredzēts akūtas saskares ar asinīm, kuras satur hepatīta B virsmas antigēnu (HBsAg), ārstēšanai. Uzņēmuma meitasuzņēmums ADMA BioCenters pārvalda plazmas savākšanas iekārtas Amerikas Savienotajās Valstīs. Tās plazmas savākšanas centru segments nodrošina daļu asins plazmas tās kandidātproduktu ražošanai.
| Industry: | Biopharmaceuticals |
C/O Adma Biologics, Inc.
465 State Route 17
RAMSEY
NEW JERSEY 07446
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com